Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity.

Swartz TH, Palermo AS, Masur SK, Aberg JA.

J Infect Dis. 2019 Aug 20;220(Supplement_2):S33-S41. doi: 10.1093/infdis/jiz174.

PMID:
31430380
2.

Low level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.

Fleming J, Mathews WC, Rutstein RM, Aberg J, Somboonwit C, Cheever LW, Berry SA, Gebo KA, Moore RD; HIV Research Network.

AIDS. 2019 Jul 10. doi: 10.1097/QAD.0000000000002306. [Epub ahead of print]

PMID:
31306175
3.

Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.

Wang L, Krebs E, Min JE, Mathews WC, Nijhawan A, Somboonwit C, Aberg JA, Moore RD, Gebo KA, Nosyk B; HIV Research Network.

Lancet HIV. 2019 Aug;6(8):e531-e539. doi: 10.1016/S2352-3018(19)30148-1. Epub 2019 Jul 11.

PMID:
31303557
4.

Targeting thrombogenicity and inflammation in chronic HIV infection.

O'Brien MP, Zafar MU, Rodriguez JC, Okoroafor I, Heyison A, Cavanagh K, Rodriguez-Caprio G, Weinberg A, Escolar G, Aberg JA, Badimon JJ.

Sci Adv. 2019 Jun 12;5(6):eaav5463. doi: 10.1126/sciadv.aav5463. eCollection 2019 Jun.

5.

Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease.

Åberg J, Hasselgren M, Montgomery S, Lisspers K, Ställberg B, Janson C, Sundh J.

Int J Chron Obstruct Pulmon Dis. 2019 May 7;14:961-969. doi: 10.2147/COPD.S193311. eCollection 2019.

6.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS; REPRIEVE Investigators.

Am Heart J. 2019 Jun;212:23-35. doi: 10.1016/j.ahj.2018.12.016. Epub 2019 Mar 4.

PMID:
30928825
7.

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Hoffmann U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, Aluru JS, Lee S, Arifovic N, Overton ET, Fichtenbaum CJ, Aberg JA, Alston-Smith B, Klingman KL, Waclawiw M, Burdo TH, Williams KC, Zanni MV, Desvigne-Nickens P, Cooper-Arnold K, Fitch KV, Ribaudo H, Douglas PS, Grinspoon SK; REPRIEVE Investigators.

Am Heart J. 2019 Jun;212:1-12. doi: 10.1016/j.ahj.2019.02.011. Epub 2019 Mar 4.

PMID:
30928823
8.

Discontinuity in Medicaid Coverage Among Young Adults with HIV.

Rusley JC, Monroe A, Matson P, Gebo KA, Nonyane BAS, Minkovitz CS, Agwu A, Emerson M, Moore R, Rutstein R, Aberg J, Nijhawan A, Boswell S, Sanders R; HIV Research Network.

AIDS Patient Care STDS. 2019 Mar;33(3):89-92. doi: 10.1089/apc.2018.0272. No abstract available.

PMID:
30844306
9.

HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015.

Radwan D, Cachay E, Falade-Nwulia O, Moore RD, Westergaard R, Mathews WC, Aberg J, Cheever L, Gebo KA; HIV Research Network.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):559-567. doi: 10.1097/QAI.0000000000001949.

10.

HIV viral suppression after transition from having no healthcare coverage and relying on Ryan White HIV/AIDS Program Support to Medicaid or private health insurance.

Raifman J, Althoff K, Rebeiro PF, Cheever LW, Hauck H, Aberg J, Gebo K, Moore R, Berry SA; The HIV Research Network.

Clin Infect Dis. 2018 Dec 24. doi: 10.1093/cid/ciy1088. [Epub ahead of print]

PMID:
30590421
11.

Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network.

Griffith DC, Farmer C, Gebo KA, Berry SA, Aberg J, Moore RD, Gaur AH, Mathews WC, Beil R, Korthuis PT, Nijhawan AE, Rutstein RM, Agwu AL; HIV Research Network.

HIV Med. 2019 Feb;20(2):169-174. doi: 10.1111/hiv.12695. Epub 2018 Dec 18.

PMID:
30561888
12.

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.

Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaau4711. doi: 10.1126/scitranslmed.aau4711.

13.

Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial.

Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, de Filippi C, Sponseller CA, Lee H, Grundberg I, Thompson MA, Aberg JA, Grinspoon SK.

EBioMedicine. 2018 Sep;35:58-66. doi: 10.1016/j.ebiom.2018.08.039. Epub 2018 Aug 31.

14.

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.

Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA.

Papillomavirus Res. 2018 Dec;6:15-21. doi: 10.1016/j.pvr.2018.08.002. Epub 2018 Aug 16.

15.

The Rapid Prediction of Carbapenem Resistance in Patients With Klebsiella pneumoniae Bacteremia Using Electronic Medical Record Data.

Sullivan T, Ichikawa O, Dudley J, Li L, Aberg J.

Open Forum Infect Dis. 2018 Apr 28;5(5):ofy091. doi: 10.1093/ofid/ofy091. eCollection 2018 May.

16.

Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332.

Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AM.

Medicine (Baltimore). 2018 Jun;97(22):e10955. doi: 10.1097/MD.0000000000010955.

17.

Factors Associated With Gaps in Medicaid Enrollment Among People With HIV and the Effect of Gaps on Viral Suppression.

Monroe AK, Myint L, M Rutstein R, Aberg J, L Boswell S, L Agwu A, A Gebo K, D Moore R; HIV Research Network.

J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):413-420. doi: 10.1097/QAI.0000000000001702.

PMID:
29697594
18.

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014.

Sundh J, Åberg J, Hasselgren M, Montgomery S, Ställberg B, Lisspers K, Janson C.

Eur Clin Respir J. 2017 Dec 4;4(1):1409060. doi: 10.1080/20018525.2017.1409060. eCollection 2017.

19.

Human Immunodeficiency Virus Medicine Association Pain Management Guidelines Needed to Curb Opioid Epidemic.

Gandhi V, Nurutdinova D, Milunka Kojic E, Aberg JA.

Clin Infect Dis. 2018 Mar 19;66(7):1152-1153. doi: 10.1093/cid/cix932. No abstract available.

PMID:
29088381
20.

Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome.

George V, Harrison L, Roach M, Li XD, Tierney C, Fischl MA, Aberg J, Tebas P, Asmuth DM, Pollard RB, Godfrey C, Pahwa S; AIDS Clinical Trials Group A5202 Study Team.

J Infect Dis. 2017 Nov 27;216(9):1159-1163. doi: 10.1093/infdis/jix460.

21.

Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities.

Aberg JA, Blankson J, Marrazzo J, Adimora AA.

J Infect Dis. 2017 Sep 15;216(suppl_5):S606-S610. doi: 10.1093/infdis/jix332.

PMID:
28938047
22.

Assessing Antiretroviral Use During Gaps in HIV Primary Care Using Multisite Medicaid Claims and Clinical Data.

Monroe AK, Fleishman JA, Voss CC, Keruly JC, Nijhawan AE, Agwu AL, Aberg JA, Rutstein RM, Moore RD, Gebo KA; HIV Research Network.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):82-89. doi: 10.1097/QAI.0000000000001469.

23.

Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004-2014.

Raifman JR, Gebo KA, Mathews WC, Korthuis PT, Ghanem KG, Aberg JA, Moore RD, Nijhawan AE, Monroe AK, Berry SA; HIV Research Network.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):409-416. doi: 10.1097/QAI.0000000000001514.

24.

Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status.

Dittmer DP, Tamburro K, Chen H, Lee A, Sanders MK, Wade TA, Napravnik S, Webster-Cyriaque J, Ghannoum M, Shiboski CH, Aberg JA.

AIDS. 2017 Sep 24;31(15):2077-2084. doi: 10.1097/QAD.0000000000001589.

25.

Aging with HIV in the ART era.

Kaplan-Lewis E, Aberg JA, Lee M.

Semin Diagn Pathol. 2017 Jul;34(4):384-397. doi: 10.1053/j.semdp.2017.04.002. Epub 2017 Apr 6. Review.

PMID:
28552209
26.

A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.

O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA.

Open Forum Infect Dis. 2017 Jan 19;4(1):ofw278. doi: 10.1093/ofid/ofw278. eCollection 2017 Winter.

27.

[Reintroduce clinical social medicine].

Halldin J, Ågren G, Svanström L, Åberg J.

Lakartidningen. 2017 Apr 26;114. pii: EMEW. Swedish. No abstract available.

28.

Reply to Allan-Blitz and Klausner.

Gaisa M, Sigel K, Aberg J, Cespedes M.

Clin Infect Dis. 2017 Jul 1;65(1):180-181. doi: 10.1093/cid/cix330. No abstract available.

PMID:
28419215
29.

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.

Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA.

Lancet HIV. 2017 Jul;4(7):e284-e294. doi: 10.1016/S2352-3018(17)30075-9. Epub 2017 Apr 13. Erratum in: Lancet HIV. 2017 Jul;4(7):e283.

PMID:
28416195
30.

Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).

Nixon DE, Bosch RJ, Chan ES, Funderburg NT, Hodder S, Lake JE, Lederman MM, Klingman KL, Aberg JA; AIDS Clinical Trials Group Study A5275 Team.

J Clin Lipidol. 2017 Jan - Feb;11(1):61-69. doi: 10.1016/j.jacl.2016.09.017. Epub 2016 Oct 5.

31.

JCL roundtable: Managing lipid disorders in patients with HIV.

Brown WV, Aberg JA, Aspry KE, Longenecker CT, Myerson M.

J Clin Lipidol. 2017 Jan - Feb;11(1):4-11. doi: 10.1016/j.jacl.2016.12.003. Epub 2016 Dec 14. Review.

PMID:
28391909
32.

Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.

Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, McCurdy Pate M, Aberg JA, Zanni MV, Grinspoon SK.

AIDS. 2017 Mar 27;31(6):797-806. doi: 10.1097/QAD.0000000000001427.

33.

Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort.

Agwu AL, Fleishman JA, Mahiane G, Nonyane BA, Althoff KN, Yehia BR, Berry SA, Rutstein R, Nijhawan A, Mathews C, Aberg JA, Keruly JC, Moore RD, Gebo KA; HIV Research Network.

PLoS One. 2017 Feb 9;12(2):e0171125. doi: 10.1371/journal.pone.0171125. eCollection 2017.

34.

High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines.

Gaisa M, Ita-Nagy F, Sigel K, Arens Y, Hennessy MA, Rodriguez-Caprio G, Mullen M, Aberg JA, Cespedes M.

Clin Infect Dis. 2017 Feb 1;64(3):289-294. doi: 10.1093/cid/ciw729. Epub 2016 Nov 9.

PMID:
27965301
35.

Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.

Kaplan-Lewis E, Aberg JA, Lee M.

Curr HIV/AIDS Rep. 2016 Oct;13(5):297-308. doi: 10.1007/s11904-016-0331-y. Review.

PMID:
27562769
36.

Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways.

Gusella GL, Teixeira A, Aberg J, Uversky VN, Mosoian A.

PLoS One. 2016 Jun 16;11(6):e0156486. doi: 10.1371/journal.pone.0156486. eCollection 2016.

37.

Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332.

Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AM, Aberg JA.

Inflammation. 2016 Aug;39(4):1354-62. doi: 10.1007/s10753-016-0367-6.

38.

Prediabetes and diabetes among HIV-infected adults in Cameroon.

Rhee JY, Bahtila TD, Palmer D, Tih PM, Aberg JA, LeRoith D, Jao J.

Diabetes Metab Res Rev. 2016 Sep;32(6):544-9. doi: 10.1002/dmrr.2792. Epub 2016 Apr 6.

39.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel.

J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002. Epub 2015 Sep 18. Erratum in: J Clin Lipidol. 2016 Jan-Feb;10(1):211. Underberg, James A [added].

40.

High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group.

Shiboski CH, Chen H, Secours R, Lee A, Webster-Cyriaque J, Ghannoum M, Evans S, Bernard D, Reznik D, Dittmer DP, Hosey L, Sévère P, Aberg JA; Oral HIV/AIDS Research Alliance, Subcommittee of the AIDS Clinical Trial Group.

PLoS One. 2015 Jul 6;10(7):e0131001. doi: 10.1371/journal.pone.0131001. eCollection 2015.

41.

Management of lipid disorders in patients living with HIV.

Myerson M, Malvestutto C, Aberg JA.

J Clin Pharmacol. 2015 Sep;55(9):957-74. doi: 10.1002/jcph.473. Epub 2015 Jun 23. Review.

PMID:
25651539
42.

Design aspects of a case-control clinical investigation of the effect of HIV on oral and gastrointestinal soluble innate factors and microbes.

Phelan JA, Abrams WR, Norman RG, Li Y, Laverty M, Corby PM, Nembhard J, Neri D, Barber CA, Aberg JA, Fisch GS, Poles MA, Malamud D.

PLoS One. 2014 Nov 19;9(11):e112901. doi: 10.1371/journal.pone.0112901. eCollection 2014.

43.

Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction.

Teixeira A, Yen B, Gusella GL, Thomas AG, Mullen MP, Aberg J, Chen X, Hoshida Y, van Bakel H, Schadt E, Basler CF, García-Sastre A, Mosoian A.

J Infect Dis. 2015 May 1;211(9):1467-75. doi: 10.1093/infdis/jiu643. Epub 2014 Nov 17.

44.

Catalytic coherence.

Åberg J.

Phys Rev Lett. 2014 Oct 10;113(15):150402. Epub 2014 Oct 7.

PMID:
25375693
45.

Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.

Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6. doi: 10.1097/QAI.0000000000000333.

46.

Self-Perception of HIV Risk and Candidacy for Pre-Exposure Prophylaxis Among Men Who Have Sex with Men Testing for HIV at Commercial Sex Venues in New York City.

Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D.

LGBT Health. 2014 Sep;1(3):218-24. doi: 10.1089/lgbt.2013.0046. Epub 2014 Jun 17.

PMID:
26789715
47.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA; International Antiviral Society-USA Panel.

JAMA. 2014 Jul 23-30;312(4):410-25. doi: 10.1001/jama.2014.8722.

PMID:
25038359
48.

Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors.

Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D.

J Immunol. 2014 Aug 1;193(3):1047-54. doi: 10.4049/jimmunol.1302936. Epub 2014 Jun 23.

49.

A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):399-406. doi: 10.1097/QAI.0000000000000195.

50.

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.

Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S.

Clin Infect Dis. 2014 Jul 1;59(1):127-35. doi: 10.1093/cid/ciu238. Epub 2014 Apr 9.

Supplemental Content

Support Center